Eckert & Ziegler Reduces Dividend to Finance Future Investments. Earnings Growth Expected for 2024. – Biotech Investments

Berlin, 19 March 2024 – The Supervisory Board and Executive Board of Eckert & Ziegler (ISIN DE0005659700, TecDAX) today decided to propose to the Annual General Meeting a reduced dividend of € 0.05 per share entitled to a dividend. The liquidity thus remaining in the company will be used to finance new high-return projects in the continuously growing market for radiopharmaceuticals. This includes, in particular, the expansion of global production capacities. The dividend reduction is also intended to ensure greater independence from external financing.

In addition to the reduced dividend, EZAG shareholders are to receive one additional Pentixapharm share for each EZAG share in the course of the planned split-off of Pentixapharm AG.

In the 2023 financial year, the Eckert & Ziegler Group increased sales by 11% to € 246.1 million. Net profit for the year amounted to € 26.3 million corresponding to earnings per share of € 1.26.

For the 2024 financial year, the Executive Board expects sales of just under € 265 million and EBIT from continuing operations before one-off effects of around € 50 million.

The detailed annual financial statements for 2023 will be published on March 22, 2024.

For enquiries please contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com